Elevai reports breakthrough in skin health proteins

NEWPORT BEACH, Calif. - Elevai Labs, Inc. (NASDAQ: ELAB), a biopharmaceutical company specializing in medical aesthetics, announced today findings from a study indicating that their proprietary exosomes may contain a unique protein profile with potential benefits for skin health. The research, conducted in partnership with Dalhousie University, found that Elevai's exosomes, derived from human umbilical cord mesenchymal stem cells (hUMSC), showcased over 800 proteins linked to wound healing, immune regulation, and extracellular matrix (ECM) remodeling.

This study, led by Dr. Stanislav Sokolenko of Dalhousie University, compared the protein content of Elevai's exosomes with 54 other published exosome protein sets. The results revealed that Elevai's exosomes were significantly enriched in proteins that are typically depleted with age and are crucial in preventing skin thinning, elasticity loss, and wrinkle formation. Transmission electron microscopy confirmed typical exosome morphology and size.

Elevai's CEO, Dr. Jordan R. Plews, emphasized the potential of their Precision Regenerative Exosome Technology (PREx™) to produce exosomes with a distinct and beneficial protein profile. He stated that this could address common skin concerns such as firmness, oxidative stress, photodamage, and texture.

The company is planning further studies to expand protein research and explore the impact of their exosomes on skin functions. These studies may also contribute to the development of synthetic exosomes for broader applications, including bone regeneration and immune regulation.

Elevai anticipates releasing the complete dataset by the end of the year. The company, which focuses on innovations for skin aesthetics and treatments related to obesity and metabolic health, aims to transform personal health and beauty through scientific research.

It should be noted that the information in this article is based on a press release statement. Elevai has a limited operational history and any forward-looking statements are not guarantees of future performance. The company's ability to bring its product candidates to market and secure additional funding remains subject to various risks and uncertainties.

In other recent news, Elevai Labs Inc. has made several strategic moves. The pharmaceutical company has amended its license agreement with INmune Bio Inc., revising terms related to the technology transfer fee. The original agreement gave Elevai exclusive rights to develop, manufacture, and commercialize INmune's EMx technology.

In a bid to increase capital flexibility, Elevai Labs has also secured a $200,000 unsecured credit line from NorthStrive Fund II LLP. This credit line carries a 20% interest rate per annum on the outstanding principal balance.

Further, the company has announced the creation of two wholly owned subsidiaries, Elevai Biosciences, Inc., and Elevai Skincare, Inc., focusing on aesthetic medicines and skincare brand success, respectively. Elevai Labs has also acquired exclusive licensing rights for two novel drug candidates from South Korean company MOA Life Plus Co., Ltd, targeting obesity treatment and muscle loss prevention.

Lastly, Elevai Labs has entered an exclusive distribution agreement with ILIA International Ltd. for its exosome-based skincare products in Taiwan. These are the recent developments from Elevai Labs.

InvestingPro Insights

Elevai Labs, Inc. (ELAB) has been making strides in the biopharmaceutical sphere with its innovative research into exosomes and their potential for skin health. As investors look at the company's prospects, certain financial metrics and InvestingPro Tips can provide a deeper understanding of its market position.

InvestingPro Data indicates a notable gross profit margin of 69.25% for the last twelve months as of Q2 2024, reflecting the company's effectiveness in managing its cost of goods sold relative to its revenue, which stands at 2.47M USD, with an impressive year-over-year growth of 140.04%. However, it's important to note that ELAB operates with a negative operating income margin of -195.46% during the same period, highlighting the challenges the company faces in achieving profitability.

The stock's performance has been under pressure, with the price having fallen significantly over the last year by -91.26%. This is further underscored by the InvestingPro Tip that ELAB stock is trading near its 52-week low, with only 7.0% of the price at its peak, and the recent price per share closing at 0.3 USD. The market capitalization of ELAB stands at a modest 6.18M USD.

Additionally, an InvestingPro Tip suggests that the stock is currently in oversold territory according to the Relative Strength Index (RSI), which could indicate a potential rebound or at least stabilization in the near term. Investors should also be aware that ELAB does not pay a dividend to shareholders, which could be a consideration for those seeking income-generating investments.

For those interested in exploring further, there are additional InvestingPro Tips available at https://www.investing.com/pro/ELAB, which can provide more insights into Elevai's financial health and stock performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.